MORRISVILLE, N.C.-
May 12, 2009-
Clinipace
, a growing digital clinical research organization, announces that Small Bone Innovations (SBi) has awarded four new projects to the company during the first quarter of 2009. These projects primarily include electronic data capture (EDC) and data management services.
SBi offers a broad, clinically proven portfolio of products and technologies to treat trauma and diseases in small bones and joints and has recently acquired the S.T.A.R. total ankle replacement system. “In selecting Clinipace, we found a partner who understands the culture and financial needs of a growing medical device firm. We share a common vision for more project visibility and appreciate their approach to service delivery,” said James O’Connor Vice President, Worldwide Regulatory, Quality and Clinical Affairs, Surgeons Ethics and Compliance at SBi.
“We are investing in multiple clinical projects. This requires a select group of clinical and regulatory service providers to work closely together with SBi. We turned to Clinipace to serve as the glue to hold the projects together from a data management perspective. Having complete real-time visibility into study-level information is critical to our success,” continued O’Connor.
"We’re excited to work with SBi, and we believe our approach to Right-Sized technology-driven service will contribute to the success of these projects,” said Jeff Williams, Chief Executive Officer at Clinipace.
"With a commitment to bringing affordable clinical development services to every life science firm, Clinipace continues to invest in technology and processes that bring much needed transparency to clinical research projects,” continues Williams.
About Small Bone Innovations, Inc.
Small Bone Innovations, Inc. (SBi) was founded in 2004 by Viscogliosi Brothers, LLC, (VB), a New York-based merchant banking firm that specializes in the musculoskeletal/orthopedics sector. VB created SBi as the first company to focus purely on small bones & joints. By integrating established companies and professionals in the field, SBi offers a broad, clinically proven portfolio of products and technologies to treat trauma and diseases in small bones & joints. Today, SBi has more than 130 employees at facilities in New York, NY, Morrisville, PA, Bourg-en-Bresse, France and Donaueschingen, Germany, among other locations worldwide. For more information on SBi, please visit:
www.totalsmallbone.com
About Clinipace
Clinipace is an experienced clinical research solutions company providing on-demand software and clinical services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. We serve biopharmaceutical and medical device companies as well as academic medical centers. Optimized by TEMPO™, our web-based software platform, we deliver services such as EDC, ePRO, grant management, data management, monitoring, site management, and biostatistics at a 30% – 50% savings compared to similar service providers. Learn more at
http://www.clinipace.com
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.